These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 406437)

  • 1. Phage-conversion to hemagglutinin production in Clostridium botulinum types C and D.
    Oguma K; Iida H; Shiozaki M
    Jpn J Med Sci Biol; 1977 Feb; 30(1):40-3. PubMed ID: 406437
    [No Abstract]   [Full Text] [Related]  

  • 2. Phage conversion to hemagglutinin production in Clostridium botulinum types C and D.
    Oguma K; Iida H; Shiozaki M
    Infect Immun; 1976 Sep; 14(3):597-602. PubMed ID: 786888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage-conversion of toxigenicity in Clostridium botulinum types C and D.
    Inoue K; Iida H
    Jpn J Med Sci Biol; 1971 Feb; 24(1):53-6. PubMed ID: 4931809
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of Clostridium botulinum types A and B hemagglutinins by sugars.
    DasGupta BR; Sugiyama H
    Can J Microbiol; 1977 Sep; 23(9):1257-60. PubMed ID: 332296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of hemagglutinin of Clostridium botulinum type C strain Stockholm.
    Suzuki N; Syuto B; Kubo S
    Jpn J Vet Res; 1986 Oct; 34(3-4):269-78. PubMed ID: 3546890
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitoxin responses to Clostridium botulinum vaccines types C and D in guinea pigs.
    Mathews AG
    Dev Biol Stand; 1976; 32():193-201. PubMed ID: 793915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage-conversion of toxigenicity in Clostridium botulinum types C and D.
    Iida H; Oguma K; Inoue K
    Jpn J Med Sci Biol; 1974 Apr; 27(2):101-3. PubMed ID: 4601039
    [No Abstract]   [Full Text] [Related]  

  • 8. [Extrachromosomal genetic elements of Clostridium botulinum. II. Isolation and analysis of DNA from bacteriophages of Clostridium botulinum types C and A].
    Rudoĭ BA; Telitsyn AM; Bakulina LV; Evstigneev VI
    Mol Gen Mikrobiol Virusol; 1998; (4):22-8. PubMed ID: 9987749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antigenicity of Clostridium botulinum type C toxin administered per os.
    Jansen BC; Knoetze PC; Visser F
    Onderstepoort J Vet Res; 1970 Sep; 37(3):169-71. PubMed ID: 4949136
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative immunochemical study of the hemagglutinins of Cl. botulinum A and B].
    Ivanova LG; Kliucheva VV; Blagoveshchenskiĭ VA; Lebedenko GI; Saprykina TP
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Feb; (2):48-53. PubMed ID: 404806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenic properties of type E botulinum toxoid].
    Switalska A; Trembowler P; Meisel H
    Med Dosw Mikrobiol; 1965; 17(4):305-11. PubMed ID: 5326421
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacteriophages and Toxigencity in Clostridium Botulinum types C and D.
    Oguma K; Iida H; Inove K
    Schweiz Med Wochenschr; 1975 Dec; 105(51):548-52. PubMed ID: 766180
    [No Abstract]   [Full Text] [Related]  

  • 13. Observations on receptor specific proteins. II. Haemagglutination and haemagglutination-inhibition reactions of Clostridium botulinum types A, C, D and E haemagglutinins.
    Balding P; Gold ER; Boroff DA; Roberts TA
    Immunology; 1973 Nov; 25(5):773-82. PubMed ID: 4586739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemagglutinin specificity of Cl. botulinum types A, B, and F in reaction with erythrocytes of various animals].
    Blagoveshchenskii BA; Ivanova LG; Khatuntseva NV; Kliucheva VV; Nikitina AA
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Jul; (7):47-51. PubMed ID: 56111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observation on non-converting phage; C-N 71 (author's transl)].
    Oguma K
    Hokkaido Igaku Zasshi; 1974 Mar; 49(2):137-41. PubMed ID: 4615995
    [No Abstract]   [Full Text] [Related]  

  • 16. [Molecular structure and immunochemical properties of highly purified hemagglutinin from Clostridium botulinum type A].
    Ivanova LG; Blagoveshchenskiĭ VA; Vinogradova ID; Kolesnikova VA; Ugriumova GA
    Biokhimiia; 1983 Sep; 48(9):1548-54. PubMed ID: 6414537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The hemagglutinin of Clostridium botulinum. Extraction, chemical characteristics and serologic specificity].
    Ivanova LG
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Mar; 0(3):14-8. PubMed ID: 47673
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of structural genes for Clostridium botulinum type C neurotoxin-converting phage particles.
    Hwang HJ; Lee JC; Yamamoto Y; Sarker MR; Tsuchiya T; Oguma K
    FEMS Microbiol Lett; 2007 May; 270(1):82-9. PubMed ID: 17302935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lack of identity between hemagglutinin and the toxin of type A botulinal organism.
    LAMANNA C; LOWENTHAL JP
    J Bacteriol; 1951 Jun; 61(6):751-2. PubMed ID: 14850434
    [No Abstract]   [Full Text] [Related]  

  • 20. [Phage conversion of Clostridium novyi type A (author's transl)].
    Schallehn G; Eklund MW; Brandis H
    Zentralbl Bakteriol A; 1980 Jun; 247(1):95-100. PubMed ID: 7434996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.